Company profile
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst
NASDAQ: STLNW · Healthcare · Medical - Care Facilities
#211 of 1,418 Healthcare companies by revenue71st-percentile growth
EA Score
59CFH 55DQ —GM 80SS 41
v0.1 · 45/100 weight · provisional
↑ growth stability, workforce scale · ↓ listing tenure, disclosure history
Methodology →Revenue TTM
$587.2M
Rev growth YoY (TTM)
+38.4%
Net income (FY)
-$60.6M
Employees
641
as of 2026-08-06
Market cap
$5.0M
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$502.7M$502.7M2025
Net income-$60.6M-$60.6M2025
Operating income-$36.1M-$36.1M2025
Total assets$164.7M$164.7M2025
Liabilities$180.4M$180.4M2025
Equity-$15.7M-$15.7M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst’s revenue?
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst booked $502.7M in FY2025 revenue, growing 28% year over year — faster than most Healthcare companies we track, at a -12.1% net margin.
Peers · Healthcare
Alzamend Neuro Inc——Cadrenal Therapeutics, Inc. Common Stock——CordovaCann Corp.——Qscreen Ai Inc.——Xcelerate Inc.——LianBio——Neighbors
Los Angeles →Key facts
CEODaniel Virnich
SectorHealthcare
IndustryMedical - Care Facilities
HeadquartersCerritos, CA
ExchangeNASDAQ: STLNW
Employees641
IPO date2026-08-04
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.